BRPI0520167A2 - formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero - Google Patents

formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero

Info

Publication number
BRPI0520167A2
BRPI0520167A2 BRPI0520167-5A BRPI0520167A BRPI0520167A2 BR PI0520167 A2 BRPI0520167 A2 BR PI0520167A2 BR PI0520167 A BRPI0520167 A BR PI0520167A BR PI0520167 A2 BRPI0520167 A2 BR PI0520167A2
Authority
BR
Brazil
Prior art keywords
menthol
mixture
poloxamer
peg
surfactant mixture
Prior art date
Application number
BRPI0520167-5A
Other languages
English (en)
Inventor
Moshe Flashner-Barak
E Itzhak Lerner
Vered Rosenberger
Noami Moldavski
Original Assignee
Teva Pharmaceutical Ind Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Ind Ltda filed Critical Teva Pharmaceutical Ind Ltda
Publication of BRPI0520167A2 publication Critical patent/BRPI0520167A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAÇÕES APRIMORADAS DE FENOFIBRATO CONTENDO MENTOL OU UMA MISTURA DE PEG/POLOXÂMERO. A invenção proporciona pelo menos uma composição para o tratamento de níveis elevados de triglicérides, consistindo de uma quantidade terapeuticaInente eficaz de fenofibrato ou outro fibrato intimamente associado ao mentol ou uma mistura surfactante, em que o mentol pode ser mentol ou mistura surfactante de mentol, e em que a mistura surfactante pode ser uma mistura de um polietileno glicol e um poloxâmero, tais como PEG (1000) e poloxâmero (407) A invenção também provê um método para o tratamento de níveis elevados de triglicérides em um sujeito, que consiste em administrar ao sujeito uma composição que consiste de uma quantidade terapeuticamente efetiva de fenofibrato ou outro fibrato e mentol ou uma mistura surfactante, em que o fenofibrato ou o outro fibrato está em associação intima com o mentol ou mistura surfactante, em que o mentol pode ser mentol ou mistura surfactante de mentol, e em que a mistura surfactante pode ser uma mistura de um polietileno glicol e um poloxâmero, tais como PEG (1000) e poloxâmero (407)
BRPI0520167-5A 2005-03-30 2005-12-29 formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero BRPI0520167A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66619205P 2005-03-30 2005-03-30
PCT/US2005/047676 WO2006107357A1 (en) 2005-03-30 2005-12-29 Improved formulations of fenofibrate containing menthol or a peg/poloxamer mixture

Publications (1)

Publication Number Publication Date
BRPI0520167A2 true BRPI0520167A2 (pt) 2009-04-22

Family

ID=35058530

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0520138-1A BRPI0520138A2 (pt) 2005-03-30 2005-07-18 formulações aprimoradas de fenofibrato contendo mentol ou peg/poloxámero
BRPI0520167-5A BRPI0520167A2 (pt) 2005-03-30 2005-12-29 formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0520138-1A BRPI0520138A2 (pt) 2005-03-30 2005-07-18 formulações aprimoradas de fenofibrato contendo mentol ou peg/poloxámero

Country Status (12)

Country Link
US (1) US20060222706A1 (pt)
EP (2) EP1861084A1 (pt)
JP (2) JP2008505934A (pt)
KR (2) KR20070113289A (pt)
CN (3) CN101212962A (pt)
AU (2) AU2005330266A1 (pt)
BR (2) BRPI0520138A2 (pt)
CA (2) CA2601372A1 (pt)
EA (2) EA200701750A1 (pt)
IL (2) IL185735A0 (pt)
MX (2) MX2007011858A (pt)
WO (2) WO2006107316A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003813A (es) * 2003-10-10 2006-06-14 Lifecycle Pharma As Forma solida de dosificacion que comprende un fibrato y una estatina.
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
JP5069001B2 (ja) * 2003-10-10 2012-11-07 ベロクシス ファーマシューティカルズ エー／エス フィブラートを含む固体投与形態
US7569612B1 (en) 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
JP2013047282A (ja) * 2006-08-31 2013-03-07 Aska Pharmaceutical Co Ltd フェノフィブラート含有組成物
JP5186159B2 (ja) * 2006-08-31 2013-04-17 あすか製薬株式会社 フェノフィブラート含有組成物
WO2008104852A2 (en) * 2007-02-26 2008-09-04 Wockhardt Research Centre Pharmaceutical compositions comprising adsorbate of fenofibrate
CN102238941A (zh) * 2008-09-17 2011-11-09 迈兰实验室公司 颗粒、制备它们的方法和包含它们的药物产品
US8632846B2 (en) * 2010-09-17 2014-01-21 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
JP6149865B2 (ja) * 2011-12-14 2017-06-21 エルテーエス ローマン テラピー−ジステーメ アーゲー フェノフィブラートのための強化された溶解速度を備えたウェーハ及びカプセル製剤
WO2014091318A1 (en) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6814977B1 (en) * 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6383517B1 (en) * 1999-01-29 2002-05-07 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6719999B2 (en) * 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
ATE329579T1 (de) * 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
EP1255565A1 (de) * 2000-01-13 2002-11-13 MERCK PATENT GmbH Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler
DE60129573T2 (de) * 2000-09-20 2008-04-17 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
EP2087882A1 (en) * 2002-03-26 2009-08-12 Teva Pharmaceutical Industries Ltd. Drug microparticles
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
EP1596832A2 (en) * 2003-02-20 2005-11-23 Teva Pharmaceutical Industries Ltd. Menthol solutions of drugs
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
JP5069001B2 (ja) * 2003-10-10 2012-11-07 ベロクシス ファーマシューティカルズ エー／エス フィブラートを含む固体投与形態
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
MXPA06003813A (es) * 2003-10-10 2006-06-14 Lifecycle Pharma As Forma solida de dosificacion que comprende un fibrato y una estatina.
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
WO2006037348A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and a statin

Also Published As

Publication number Publication date
MX2007012125A (es) 2007-12-07
CN101212962A (zh) 2008-07-02
WO2006107316A1 (en) 2006-10-12
CN101217951A (zh) 2008-07-09
EP1707196A1 (en) 2006-10-04
CA2601372A1 (en) 2006-10-12
AU2005330320A1 (en) 2006-10-12
JP2008505934A (ja) 2008-02-28
JP2008534584A (ja) 2008-08-28
EA200701986A1 (ru) 2008-04-28
KR20070113289A (ko) 2007-11-28
AU2005330266A1 (en) 2006-10-12
MX2007011858A (es) 2008-03-25
EA200701750A1 (ru) 2008-02-28
KR20070120990A (ko) 2007-12-26
IL185734A0 (en) 2008-01-06
CN101217950A (zh) 2008-07-09
US20060222706A1 (en) 2006-10-05
BRPI0520138A2 (pt) 2011-04-19
WO2006107316A8 (en) 2007-11-22
IL185735A0 (en) 2008-01-06
WO2006107357A1 (en) 2006-10-12
EP1861084A1 (en) 2007-12-05
CA2601374A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
BRPI0520167A2 (pt) formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero
EA200701751A1 (ru) Улучшенные составы фенофибрата
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
BRPI0414908A (pt) compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
NO20161808A1 (no) Sammensetninger omfattende ornitin og fenylacetat eller fenylbutyrat for å behandle hepatisk encefalopati
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
BRPI0618918B8 (pt) uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
AR055095A1 (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
ATE538801T1 (de) Therapeutische zusammensetzungen mit mindestens einem pyrrolobenzodiazepin-derivat und fludarabin
ECSP10010589A (es) Farmaco contra el cancer de higado
CU20070203A7 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
BRPI0506493A (pt) combinações terapêuticas
WO2008103993A3 (en) Compositions and methods for treating glycogen storage diseases
AR060089A1 (es) Tratamiento del dolor
AR065138A1 (es) Uso de compuestos de arsenico para el tratamiento del dolor y la inflamacion
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
JO3598B1 (ar) الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
AR063470A1 (es) Terapia combinada
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
BRPI0516077A (pt) composições antimicrobianas compreendendo um agente natural selecionado de ácido gálico, eucalipotol, naringina, um composto de ácido jasmÈnico e qualquer combinação destes
PE20080331A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2203 DE 26/03/2013.